Talking to Your Home Oncologist About NK Cell Therapy in Osaka

Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.

If you are living with cancer overseas and have heard about NK cell therapy in Japan, one of the most important conversations happens before any travel is booked: the one with your home oncologist. This article explains how international patients can approach that conversation, what information is useful to bring, and how Grand Green Osaka Umekita Clinic in Osaka can fit into the wider picture of your care.

In short, NK cell therapy is a self-pay option that is usually discussed alongside, not instead of, your standard cancer treatment. Your home team knows your history best, so involving them early helps everyone make a more informed decision. Any decision about treatment ultimately depends on a doctor’s examination and individual circumstances.

Why involve your home oncologist at all?

Your oncologist has followed your diagnosis, test results, and responses to treatment. That context matters, because immune cell therapy is generally considered in relation to your current stage of care, such as during chemotherapy, after surgery, or after treatment has finished. A clinic in Japan can only advise well if it understands what you are already receiving.

There is also a practical reason. Standard treatments such as surgery, chemotherapy, and radiation therapy have their own schedules. According to the clinic, NK cell therapy is generally intended to be used alongside these treatments, and the clinic can coordinate with the medical institution providing standard care. Coordination works best when your home doctor is aware of your plans rather than hearing about them afterward.

Some patients worry that raising the topic will upset their doctor or be taken as a lack of trust. In practice, most oncologists would rather hear about options you are considering than discover them later. Presenting it as a request for their opinion, not a decision you have already made, tends to keep the conversation constructive.

What NK cell therapy is, in plain terms

Before you speak with your oncologist, it helps to describe the therapy accurately. NK (natural killer) cells are a type of innate immune cell that circulates in the blood and can recognize and attack abnormal cells, including cancer cells and virus-infected cells, without needing instructions from other immune cells. Research has suggested that NK cell activity can decline with age, stress, and the effects of cancer itself.

In NK cell therapy, a sample of your own blood is taken, and NK cells are activated and expanded outside the body at a licensed cell processing facility. They are then returned to you by intravenous infusion. The aim is to return more NK cells with higher activity to support weakened immune function. It does not involve hospitalization, but it is not a guaranteed route to any particular outcome, and evidence from large comparative studies remains limited. You can search PubMed for current research on NK cell infusion and discuss what you find with your doctor.

Being candid about these limits will also make your conversation more credible. Your oncologist is likely to ask what evidence exists, what the goals are, and what could go wrong, and it is reasonable to say that you are still gathering information.

Information and records worth preparing

A short, organized summary makes it easier for both your home doctor and the clinic in Osaka to give useful input. Consider gathering the following, ideally with a translated or English summary if your records are in another language:

• Your diagnosis, stage, and the dates of key tests and treatments
• A list of current and past medications, including chemotherapy regimens and any immune-related drugs
• Recent blood test results and imaging reports
• Any history of autoimmune conditions, allergies, or infections
• Your current treatment plan and the date of your next scheduled visit

Having these documents to hand also helps the Osaka clinic during an initial consultation, where the doctor reviews your condition before discussing whether the therapy is appropriate for you. The documents do not guarantee that treatment will be offered; eligibility is decided by the doctor after assessment.

Questions to bring to your home oncologist

Rather than asking a general question such as whether NK cell therapy is a good idea, specific questions tend to produce more useful answers. For example:

• Is there any reason, given my current treatment, to avoid or delay an immune cell therapy?
• Would you be willing to share my records with a clinic in Japan, and in what format?
• Which test results or symptoms should I report to you after returning home?
• If I experience fever, fatigue, or other symptoms, who should I contact first?
• Can you continue to monitor me as usual while I also receive therapy in Japan?

Note that your doctor may have reservations. Taking these seriously is part of responsible decision-making. NK cell therapy is a self-pay treatment not covered by insurance, and it should never be considered a replacement for standard treatment that your oncologist recommends.

Understanding the legal framework and costs in Japan

In Japan, cell-based therapies of this kind are provided under the Act on the Safety of Regenerative Medicine, through a regenerative medicine provision plan that has been submitted to and accepted by the authorities. Your oncologist may ask about this, so it is useful to be able to explain that the clinic operates within this legal system. This is a framework for oversight and does not mean that results are assured.

NK cell therapy at Grand Green Osaka Umekita Clinic is a self-pay treatment. Fees, the number of treatments, the treatment period, risks, and possible side effects, such as temporary fever or fatigue, should all be confirmed with the doctor at consultation and on the clinic’s fee and FAQ pages before you decide. Asking for these details in writing can also help you discuss them with your home team and with family members.

Taking the next step from Osaka

Once you have spoken with your oncologist, you can contact the clinic in Osaka (Umeda) to ask about a consultation. The clinic provides an information page for international patients in multiple languages, which can help you prepare questions in advance. If you decide to proceed, tell your home doctor which dates you plan to travel and what you expect after the treatment, so that monitoring at home continues smoothly.

Whatever you decide, keep your standard care on track, ask for explanations in your own language, and take the time you need. A conversation with your home oncologist, followed by a doctor’s examination in Osaka, is a reasonable way to weigh this option carefully.

• Talk to your oncologistShare your plans early
• Prepare your recordsTests, drugs, treatment plan
• Keep standard careDiscuss alongside, not instead
• Confirm self-pay detailsFees, risks, side effects

This figure is a conceptual diagram summarizing the article

References

• PubMed: Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. (2020)
• PubMed: CD371-targeted CAR T cells secreting interleukin-18 exhibit robust expansion and clear refractory acute myeloid leukemia. (2025)
• PubMed: NK cell-based cancer immunotherapy: from basic biology to clinical application. (2015)
• PubMed: Natural Killer Cells as Allogeneic Effectors in Adoptive Cancer Immunotherapy. (2019)
• PubMed: Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial. (2026)
• PMC: Targeting immune checkpoints: how to use natural killer cells for fighting against solid tumors. (2023)
• PMC: Cell therapy for brain tumors: The first 60 years. (2026)
• PMC: Preservation of cell-based immunotherapies for clinical trials. (2019)
• MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan

Supervising Physician

Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic

Hidenori Shimada

Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.

* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.